Six Peptides in the HHS Plan: The Uses FDA Actually Evaluated

Six names are travelling together across peptide feeds: BPC-157, TB-500, KPV, MOTS-c, Semax and epitalon. They appear in Reuters reporting about the new HHS compounding plan. Putting them into one announcement, however, does not give them one shared medical purpose or one shared body of evidence.

The FDA's July 23–24 advisory meeting is a useful corrective. Its agenda names the substances and the uses the agency evaluated. Those uses are narrower, and sometimes quite different, from the claims most often encountered in wellness marketing.

These are evaluation topics, not approved indications. The agenda also includes emideltide, which is separate from the six named in October reporting.

The July agenda identifies BPC-157 free base and BPC-157 acetate and lists ulcerative colitis as the use evaluated. That is a specific inflammatory bowel condition. It is not an endorsement of using BPC-157 for every painful tendon, training injury or recovery goal.

The difference matters because an ingredient can attract interest across many biological pathways while having very little reliable clinical evidence for any particular one. A regulatory discussion about one proposed use cannot establish effectiveness for a different condition.

KPV free base and acetate were evaluated for wound healing and inflammatory conditions. TB-500 free base and acetate were evaluated for wound healing. The agenda treats them as separate substances, with separate briefing documents.

A shared phrase such as wound healing does not demonstrate that the substances work equally well, have interchangeable safety profiles or can substitute for each other. It identifies what was under discussion. The underlying studies still need to show which patients were studied, what outcomes were measured and how the comparison was made.

It also does not establish the benefits of combining substances. Claims about a named stack require evidence about the actual combination, rather than a collection of separate mechanistic arguments.

The committee's published agenda lists obesity and osteoporosis for MOTS-c, insomnia for epitalon, and cerebral ischemia, migraine and trigeminal neuralgia for Semax. These are proposed uses considered during the review, not a list of approved indications.

That distinction stops a common error: turning a table headed uses evaluated into a table of proven benefits. Someone reading about MOTS-c for weight management, for example, still needs evidence about the administered substance, the study population and the measured outcome. The fact that a naturally occurring peptide has a biological role does not establish that a commercial preparation will deliver a clinical benefit.

The agenda repeatedly distinguishes free-base and acetate forms. That detail can disappear when discussions shorten everything to a familiar name. For regulatory and quality purposes, the precise ingredient matters.

The same care is needed when reading research. A trial involving a related molecule, a different formulation or a different administration route may help explain a hypothesis without proving what a product advertised under a shorter name will do.

The October announcement concerns a potential route for compounding under section 503A. The federal notice describes a draft enforcement policy while rulemaking continues. It does not supply a new clinical trial for any of these six substances.

FDA July meeting agenda: ingredient forms, evaluated uses and briefing documents

HHS Federal Register notice for the draft compounding policy

This article reports on policy and research reviewed on October 29, 2026. It is for educational purposes only and is not medical advice. No individual product, seller or treatment is endorsed.